FDA
label_change
· 2011-06-03
FDA Approved: EXFORGE HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)
Summary
FDA approved a supplemental application for EXFORGE HCT (amlodipine/valsartan/hydrochlorothiazide) from Novartis, updating the product labeling.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for EXFORGE HCT (AMLODIPINE VALSARTAN AND HYDROCHLOROTHIAZIDE)